FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.			APPLICATION NO			
		PATENT AND TRADEMARK OFFICE				800.1019			10/529,028		
LIST OF PRIOR ART CITED BY APPLICANT						APPLICANT Sarina STRIEM et al.					
		(Use several sheet		March 24, 2005			1625				
			U.S. P.	ATENT DOCUM	IENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NA	NAME CL			SUB- CLASS	FILING DATE		
INITIAL	A01	DOCOMENT NOMBER	DAIL	1100			UE IGG	CDAGG	-		
	A02										
	A03										
	17.00		FOREIGN	PATENT DOC	UMENT	s					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Г	TRANSLA	TION		
		DOCUMENT NUMBER DATE COUNTRY			CEAGG	OLAGO				NO	
/VO/	A04	99/16741	04/08/1999	PCT							
	A05					<u> </u>					
	A06										
	A07									_	
	A08										
	A09				1						
	A10						1				
	A11				1	1					
	A12										
		OTHER REFERE	NCES (Includ	ding Author Title	Date	Pertine	nt Pages	. Etc.)			
	140			-					ool gorgh-	nl n	
/VO/	A13	Krakovsky, M. et al., *DP-b99: A novel membrane-targeted compound active against global and focal cerebral ischemia,* Physiological Imaging of the Brain with PET, (2001), pp. 347-352.									
	A14	Woessner, J.F., "Matrix metalloproteinase inhibition. From the Jurassic to the third millennium," Ann. NY Acad. Sci., (1999), 878: 388-403.									
	A15	Ferry, G. et al., "A zin Pharmacol., Vol. 351,	c chelator inhibiti		ts potent	in vitro ar	nti-invasive	effects,* E	ur. J.		
-\/-	A16	Tetsure Kuhota "Marimastat" Journal of clinical and experimental medicine, Vol. 194, No. 13 (2000), p. 988.									

EXAMINER	/Taylor Oh/ (02/15/2010)	DATE CONSIDERED	02/15/2010
*EXAMINER: Initi	al if reference considered, whether or not citation i	s in conformance with MPEP 609; Drav	v line through citation if not in

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A17 A18 A19 A20 A21 A22 A23